GRAIL, Inc.
$51.2
▲
2.59%
2026-04-21 07:10:01
grail.com
NMS: GRAL
Explore GRAIL, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.1 B
Current Price
$51.2
52W High / Low
$118.84 / $25.56
Stock P/E
—
Book Value
$63.92
Dividend Yield
—
ROCE
-18.79%
ROE
-16.07%
Face Value
—
EPS
$-11.11
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
910
Beta
—
Debt / Equity
2.13
Current Ratio
11.97
Quick Ratio
11.77
Forward P/E
-5.04
Price / Sales
12.72
Enterprise Value
$1.02 B
EV / EBITDA
-2.71
EV / Revenue
6.95
Rating
Buy
Target Price
$69.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Precipio, Inc. | $28.15 | — | $50.21 M | — | -6.84% | -2.72% | $29.8 / $5.19 | $8.18 |
| 2. | Revvity, Inc. | $93.89 | 28.42 | $10.54 B | 0.3% | 3.29% | 3.22% | $118.3 / $81.36 | $64.57 |
| 3. | Waters Corporation | $332.95 | 30.93 | $32.76 B | — | 20.92% | 29.28% | $414.15 / $275.05 | $43.01 |
| 4. | Natera, Inc. | $206.53 | — | $29.47 B | — | -15.84% | -14.32% | $256.36 / $131.81 | $12.26 |
| 5. | IDEXX Laboratories, Inc. | $580.27 | 44.49 | $46.26 B | — | 61.76% | 66.2% | $769.98 / $402.85 | $20.14 |
| 6. | Labcorp Holdings Inc. | $271.17 | 25.93 | $22.36 B | 1.07% | 9.74% | 10.51% | $293.72 / $209.38 | $104.86 |
| 7. | ENDRA Life Sciences Inc. | $6.01 | — | $7.46 M | — | -281.17% | -2.92% | $11.96 / $2.9 | $0.22 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 43.6 M | 36.19 M | 35.54 M | 31.84 M | 38.25 M | — |
| Operating Profit | -124.41 M | -125.29 M | -130.85 M | -153.61 M | -136.94 M | — |
| Net Profit | -99.18 M | -88.98 M | -113.98 M | -106.21 M | -97.07 M | — |
| EPS in Rs | -2.42 | -2.17 | -2.78 | -2.59 | -2.37 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 147.17 M | 125.59 M | 93.11 M | 55.55 M |
| Operating Profit | -534.16 M | -768.22 M | -796.92 M | -742.46 M |
| Net Profit | -408.35 M | -2.03 B | -1.47 B | -5.4 B |
| EPS in Rs | -9.95 | -49.41 | -35.73 | -131.62 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.92 B | 2.98 B | 3.91 B | 4.94 B |
| Total Liabilities | 344.15 M | 479.9 M | 267.63 M | 291.82 M |
| Equity | 2.58 B | 2.5 B | 0 M | 0 M |
| Current Assets | 953.85 M | 819.86 M | 156.06 M | 295.63 M |
| Current Liabilities | 79.67 M | 76.92 M | 163.61 M | 134.94 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -299.01 M | -577.16 M | -595.8 M | -561.31 M |
| Investing CF | -85.05 M | -551.01 M | -12.89 M | -22.86 M |
| Financing CF | 423.32 M | 1.24 B | 463.77 M | 604.82 M |
| Free CF | -299.92 M | -582.36 M | -608.69 M | -584.17 M |
| Capex | -0.91 M | -5.21 M | -12.89 M | -22.86 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 17.18% | 34.9% | 67.61% | — |
| Earnings Growth % | 79.85% | -38.3% | 72.85% | — |
| Profit Margin % | -277.47% | -1613.92% | -1574.23% | -9719.35% |
| Operating Margin % | -362.95% | -611.67% | -855.93% | -1336.56% |
| Gross Margin % | -42.52% | -62.12% | -102.69% | -209.63% |
| EBITDA Margin % | -256.72% | -485.82% | -685.48% | -1057.96% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.